Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GBL-Containing Supplements Should Be Recalled - FDA "Talk Paper"

This article was originally published in The Tan Sheet

Executive Summary

FDA will proceed with regulatory action, such as a warning letter, against gamma butyrolactone (GBL) dietary supplement producers if they do not respond to an agency request for the companies to voluntarily recall their products. The agency suggested the voluntary recall in a Jan. 21 "Talk Paper."
Advertisement

Related Content

Tiratricol Use Warning, Recall Alert Subject Of FDA "Talk Paper"
Tiratricol Use Warning, Recall Alert Subject Of FDA "Talk Paper"
GBL Would Become A DEA Controlled Substance Under House Date Rape Bill
GBL Would Become A DEA Controlled Substance Under House Date Rape Bill

Topics

Advertisement
UsernamePublicRestriction

Register

PS089327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel